Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and EGFR-TKI in advanced NSCLC
NCT03428022Phase 3Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Shenzhen People's Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03428022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428022.